Parkinson Disease
Conditions
Brief summary
The purpose of the study was to To investigate whether the administration of BIA 6-512 (25 mg, 50 mg, 75 mg and 100 mg) at steady-state affects the pharmacokinetics of levodopa when administered in combination with a single-dose of immediate release levodopa/benserazide 200/50 mg or with a single-dose of immediate release levodopa/benserazide 200/50 mg plus a single-dose of entacapone 200 mg.
Detailed description
Single centre, double-blind, randomised, placebo-controlled, rising multiple-dose study in four sequential groups of healthy male and female subjects. Eligible subjects were admitted to the Human Pharmacology Unit (UFHBIAL - Portela & Cª, SA) on the day prior to receiving the first study medication. Starting in the morning of Day 1 (first dose), subjects received BIA 6-512/Placebo thrice-daily until the morning of Day 5 (last dose). Concomitantly with the morning dose of BIA 6-512/Placebo, on Day 4 a levodopa/benserazide 200/50 mg (Madopar® 250) single-dose was administered. On Day 5, a Madopar® 250 single-dose and a entacapone 200 mg (Comtan®) single-dose were administered concomitantly with the morning dose of BIA 6-512/Placebo. In the morning of Day 4 and Day 5, products were administered in fasting of at least 8 hours and subjects remained fasted until 2 h post-dose. Subjects were resident in the UFH from admission (Day 0) until at least 24 h post last dose (Day 6); then, they were discharged and returned for the follow-up visit.
Interventions
DRUGPlacebo
1 capsule of placebo \[to be taken orally, with 240 mL of potable water\]
DRUGBIA 6-512
1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg \[to be taken orally, with 240 mL of potable water\]
DRUGMadopar® 250
Levodopa/benserazide immediate release tablets 200mg/50mg \[to be taken orally, with 240 mL of potable water\]
DRUGComtan®
Entacapone 200 mg tablets \[to be taken orally, with 240 mL of potable water\]
Sponsors
Bial - Portela C S.A.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female subjects aged between 18 and 45 years, inclusive. * Subjects of body mass index (BMI) between 19 and 30 kg/m2, inclusive. * Subjects who were healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead ECG. * Subjects who had negative tests for HBsAg, anti-HCVAb and HIV-1 and HIV-2 Ab at screening * Subjects who had clinical laboratory test results clinically acceptable at screening and admission. * Subjects who had a negative screen for alcohol and drugs of abuse at screening and admission. * Subjects who were non-smokers or who smoked ≤ 10 cigarettes or equivalent per day. * Subjects who were able and willing to gave written informed consent. * (If female) She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: double barrier, intrauterine device or abstinence. * (If female) She had a negative urine pregnancy test at screening and admission.
Exclusion criteria
* Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders. * Subjects who had a clinically relevant surgical history. * Subjects who had a clinically relevant family history. * Subjects who had a history of relevant atopy. * Subjects who had a history of relevant drug hypersensitivity. * Subjects who had a history of alcoholism or drug abuse. * Subjects who consumed more than 14 units of alcohol a week. * Subjects who had a significant infection or known inflammatory process on screening or admission. * Subjects who had acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission. * Subjects who had used medicines within 2 weeks of admission that may affect the safety or other study assessments, in the investigator's opinion. * Subjects who had previously participated in a clinical trial with BIA 6-512. * Subjects who had used any investigational drug or participated in any clinical trial within 6 months prior to screening. * Subjects who had participated in more than 2 clinical trials within the 12 months prior to screening. * Subjects who had donated or received any blood or blood products within the 3 months prior to screening. * Subjects who were vegetarians, vegans or have medical dietary restrictions. * Subjects who cannot communicate reliably with the investigator. * Subjects who were unlikely to co-operate with the requirements of the study. * Subjects who were unwilling or unable to give written informed consent. * (If female) She was pregnant or breast-feeding. * (If female) She was of childbearing potential and she did not use an effective contraceptive method (double-barrier, intra-uterine device or abstinence) or she used oral contraceptives.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Day 4 - Maximum observed plasma drug concentration (Cmax) | pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8 and 16 hours post-dose | BIA 6-512, levodopa, 3-OMD and entacapone pharmacokinetic parameters on day 4 |
| Day 4 - Time of occurrence of Cmax (tmax) | pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8 and 16 hours post-dose | BIA 6-512, levodopa, 3-OMD and entacapone pharmacokinetic parameters on day 4 |
| Day 4 - Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-t) | pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8 and 16 hours post-dose | BIA 6-512, levodopa, 3-OMD and entacapone pharmacokinetic parameters on day 4 |
| Day 4 - AUC from time zero to 8 h post-dose (AUC0-τ) | pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8 and 16 hours post-dose | BIA 6-512, levodopa, 3-OMD and entacapone pharmacokinetic parameters on day 4 |
| Day 4 - Apparent terminal elimination half-life, calculated from ln 2/λz (t1/2) | pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8 and 16 hours post-dose | BIA 6-512, levodopa, 3-OMD and entacapone pharmacokinetic parameters on day 4 |
| Day 4 - Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞) | pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8 and 16 hours post-dose | BIA 6-512, levodopa, 3-OMD and entacapone pharmacokinetic parameters on day 4 |
| Day 5 - Maximum observed plasma drug concentration (Cmax) | pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 16 and 24 hours post-dose | — |
| Day 5 - Time of occurrence of Cmax (tmax) | pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 16 and 24 hours post-dose | BIA 6-512, levodopa, 3-OMD and entacapone pharmacokinetic parameters on day 5 |
| Day 5 - Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-t) | pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 16 and 24 hours post-dose | BIA 6-512, levodopa, 3-OMD and entacapone pharmacokinetic parameters on day 5 |
| Day 5 - AUC from time zero to 8 h post-dose (AUC0-τ) | pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 16 and 24 hours post-dose | BIA 6-512, levodopa, 3-OMD and entacapone pharmacokinetic parameters on day 5 |
| Day 5 - Apparent terminal elimination half-life, calculated from ln 2/λz (t1/2) | pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 16 and 24 hours post-dose | BIA 6-512, levodopa, 3-OMD and entacapone pharmacokinetic parameters on day 5 |
| Day 5 - Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞) | pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 16 and 24 hours post-dose | BIA 6-512, levodopa, 3-OMD and entacapone pharmacokinetic parameters on day 5 |
Countries
Portugal
Outcome results
None listed